pharmaphorum

DECEMBER 16, 2020

We’ve got so many great life science assets in the UK, but there are still some gaps – manufacturing capacity being one of them.”. “We We had companies collaborating to develop laboratories. We had companies sourcing consumables for testing machines. The road to a vaccine. A collaborative future.

Vaccination 122

Vaccination Vaccine Life Science In-Vitro 122

XTalks

NOVEMBER 9, 2023

XTALKS WEBINAR: Impacts of the New IVD Regulation (IVDR) for Manufacturers and Users Live and On-Demand: Tuesday, January 9, 2024, at 10am EST (4pm CET/EU-Central) Register for this free webinar to learn about the specific compliance requirements, risk assessments and quality management changes mandated by the IVDR.

FDA Approval 64

FDA Approval HR Genotype Life Science 64

pharmaphorum

SEPTEMBER 15, 2020

Pharma’s go-to-market strategies have tended to be more traditional than those seen in non-regulated sectors, but there are some signs this is changing, with an acceleration in the pace of change forced by the COVID-19 pandemic that is allowing the industry to close its gap with faster, more nimble consumer brands. “The

Branding 124

Branding Marketing Pharma Companies Life Science 124

pharmaphorum

NOVEMBER 23, 2022

A director in life sciences consulting for EY, she works within the commercial space for such companies, as well as their clients. “My We looked at the areas of rare diseases, cell and gene therapy, vaccines – loads of different perspectives. Innovative offerings around market access. Smart reviewing: utilising AI and ML.

Life Science 98

Life Science Marketing Medicine Production 98

pharmaphorum

FEBRUARY 11, 2021

Pharma companies face many challenges when involving patients in the design of clinical trials – but doing so can have huge benefits further down the line, improving the sustainability and quality of research. There’s also that risk of a perceived coercion or influence. There’s sometimes a bit of a barrier,” he added.

Clinical Trials 92

Clinical Trials Clinical Trials Trials Clinical Research 92

pharmaphorum

APRIL 7, 2021

With other drugs in the pipeline too, van de Winkel said the company aims to continue to break new ground with next-generation antibody-based therapies. He notes that it already has 21 partnerships with pharma companies and will aim to keep more product rights than it did in the past. In good shape. We are in a crisis.

Antibody 78

Antibody Life Science Development Regulation 78

pharmaphorum

DECEMBER 15, 2022

Co-chaired by Lord James O’Shaughnessy and Professor Mike Bewick, former deputy national medical director of NHS England (present online), the NHS Innovation and Life Sciences Commission Report launch took place at One Great George Street, Westminster, on 12th December 2022. The UK as a powerhouse of research.

Life Science 96

Life Science Medicine Clinical Trials Clinical Trials 96

pharmaphorum

MAY 27, 2022

Once stakeholders are confident that technologies are adequately validated, selection based on scientific and ethical considerations can be presented to regulators in accordance with applicable legal and regulatory frameworks. There is a huge opportunity for pharma companies to capitalise on by focusing on increased DEI in clinical trials.

Clinical Trials 80

Clinical Trials Clinical Trials Trials Packaging 80

pharmaphorum

APRIL 19, 2021

UK biotech guru Clive Dix has clinched some major deals with big pharma and biotech in the last 12 months, as CEO of C4X Discovery and as head of the UK vaccines taskforce. But Dix has also been leading the UK’s Vaccine Taskforce, after taking over the hot seat in December following the departure of Kate Bingham.

Vaccination 97

Vaccination Vaccine Life Science Antibody 97

pharmaphorum

MARCH 9, 2021

Regeneron and Eli Lilly have already got antibody therapies on the market following emergency approvals by regulators including the FDA but pharma companies are beginning to focus on the threat posed by emerging variants.

Antibody 98

Antibody Life Science Scientist Vaccination 98

Drug Discovery World

JANUARY 5, 2023

Frits Stulp and Aida Demneri , partners at Deloitte (including Iperion – a Deloitte business), outline how life sciences companies can play their part in driving change. In the past two years, EU regulatory authorities accelerated processes so that vaccines and medicines could be brought to market more quickly.

Life Science 52

Life Science Production Medicine Compliance 52

pharmaphorum

NOVEMBER 6, 2020

The sharing of knowledge has already been critical in the industry’s collaborative efforts to expedite a COVID-19 vaccine, and Nikitczuk believes that this open approach should extend beyond research into the software and data tools pharma uses every day. This fragmented landscape creates issues for pharma. “If,

Life Science 52

Life Science Pharma Companies Production Development 52

Drug Discovery World

JANUARY 26, 2023

Research into HIV blossomed throughout 2022, with ViiV Healthcare’s combination therapy for HIV-1 gaining approval in Japan; and research moving forward towards a one-time treatment for HIV as well as a vaccine. According to research from Deloitte 1 , the average ROI in R&D for global pharma companies fell to just 1.2%

Development 98

Development Drugs Clinical Trials Clinical Trials 98

Drug Discovery World

SEPTEMBER 7, 2022

Artificial intelligence (AI), a branch of computer science encompassing machine learning and deep learning, and which technologies such as automation, natural language processing (NLP) and image recognition all fall into, offers significant opportunity for the life sciences industry to change how it operates. Covid-19 .

Research 52

Research Scientist Clinical Trials Clinical Trials 52

pharmaphorum

NOVEMBER 15, 2021

.” After his 11-month stint heading the agency, Califf returned to his role as a cardiologist whilst also serving as a health policy and strategy advisor to Google’s unit life sciences unit Verily and running Duke University’s Clinical Research Institute, which he founded in 1996.

Regulation 98

Regulation Life Science Pharma Companies Branding 98